CN1660351A - 一种包含有黄芪和血竭的药物组合物及其应用 - Google Patents
一种包含有黄芪和血竭的药物组合物及其应用 Download PDFInfo
- Publication number
- CN1660351A CN1660351A CN200510001987XA CN200510001987A CN1660351A CN 1660351 A CN1660351 A CN 1660351A CN 200510001987X A CN200510001987X A CN 200510001987XA CN 200510001987 A CN200510001987 A CN 200510001987A CN 1660351 A CN1660351 A CN 1660351A
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- sanguis draxonis
- application
- extract
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 26
- 239000009136 dragon's blood Substances 0.000 title abstract description 3
- 229940107666 astragalus root Drugs 0.000 title abstract 2
- 239000011347 resin Substances 0.000 title description 11
- 229920005989 resin Polymers 0.000 title description 11
- 229940079593 drug Drugs 0.000 title description 5
- 241001043298 Croton draco Species 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 13
- 208000007502 anemia Diseases 0.000 claims abstract description 11
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 7
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 6
- 239000009636 Huang Qi Substances 0.000 claims description 145
- 239000009286 sanguis draxonis Substances 0.000 claims description 109
- 239000000284 extract Substances 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 230000007812 deficiency Effects 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 208000036119 Frailty Diseases 0.000 claims description 8
- 208000037386 Typhoid Diseases 0.000 claims description 8
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 206010003549 asthenia Diseases 0.000 claims description 8
- 230000035900 sweating Effects 0.000 claims description 8
- 201000008297 typhoid fever Diseases 0.000 claims description 8
- 231100000397 ulcer Toxicity 0.000 claims description 8
- 230000017531 blood circulation Effects 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 208000001848 dysentery Diseases 0.000 claims description 6
- 206010016766 flatulence Diseases 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 235000019789 appetite Nutrition 0.000 claims description 5
- 230000036528 appetite Effects 0.000 claims description 5
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000001647 drug administration Methods 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 abstract description 5
- 206010061428 decreased appetite Diseases 0.000 abstract description 5
- 208000033065 inborn errors of immunity Diseases 0.000 abstract description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract description 3
- 240000004824 Trimezia steyermarkii Species 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 50
- 150000001875 compounds Chemical class 0.000 description 40
- 230000000694 effects Effects 0.000 description 23
- 235000006533 astragalus Nutrition 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 15
- 241000045403 Astragalus propinquus Species 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 14
- 235000021286 stilbenes Nutrition 0.000 description 14
- UCZJPQIEFFTIEV-UHFFFAOYSA-N 5-methoxy-6-methyl-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=C(C)C(=O)C=C2OC=1C1=CC=CC=C1 UCZJPQIEFFTIEV-UHFFFAOYSA-N 0.000 description 13
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 13
- 239000012567 medical material Substances 0.000 description 13
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 8
- 241001061264 Astragalus Species 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 8
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 210000004233 talus Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000015961 tonic Nutrition 0.000 description 6
- 230000001256 tonic effect Effects 0.000 description 6
- -1 triterpene glycoside triterpene glycosides Chemical class 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- MHVJRKBZMUDEEV-UHFFFAOYSA-N (-)-ent-pimara-8(14),15-dien-19-oic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)C=C1CC2 MHVJRKBZMUDEEV-UHFFFAOYSA-N 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000007919 dispersible tablet Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 229940031937 polysaccharide vaccine Drugs 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- MXYATHGRPJZBNA-UHFFFAOYSA-N 4-epi-isopimaric acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)CC1=CC2 MXYATHGRPJZBNA-UHFFFAOYSA-N 0.000 description 2
- VWNVDXRJGNLURQ-UHFFFAOYSA-N 5-methoxy-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=CC(=O)C=C2OC=1C1=CC=CC=C1 VWNVDXRJGNLURQ-UHFFFAOYSA-N 0.000 description 2
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 2
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 2
- FWKBXSPDFCAHFN-UHFFFAOYSA-N Dracorubin Natural products C1CC=2C(OC)=CC=3OC(C=45)=C(C)C(=O)C=C5OC(C=5C=CC=CC=5)=CC=4C=3C=2OC1C1=CC=CC=C1 FWKBXSPDFCAHFN-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241001002545 Engelhardia roxburghiana Species 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 241000266851 Hedysarum polybotrys Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HVPKALQHGQMJER-XOUPSZAESA-N Isoastragaloside I Chemical compound CC(=O)O[C@@H]1[C@@H](O)[C@H](OC(=O)C)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C[C@H]3[C@]4(C)C[C@H](O)[C@H]([C@]5(C)O[C@@H](CC5)C(C)(C)O)[C@@]4(C)CC[C@@]43C[C@@]42CC1 HVPKALQHGQMJER-XOUPSZAESA-N 0.000 description 2
- MSSYPWFHLFBMMP-BQAOMNQWSA-N Isoastragaloside IV Chemical compound C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)O)C)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O MSSYPWFHLFBMMP-BQAOMNQWSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- MGJLSBDCWOSMHL-WFMNFSIZSA-N Ononin Natural products O(C)c1ccc(C=2C(=O)c3c(OC=2)cc(O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc3)cc1 MGJLSBDCWOSMHL-WFMNFSIZSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 229920000473 Phlobaphene Polymers 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229930187719 Soyasaponin Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 235000006085 Vigna mungo var mungo Nutrition 0.000 description 2
- 240000005616 Vigna mungo var. mungo Species 0.000 description 2
- 208000009257 Visceral Prolapse Diseases 0.000 description 2
- 206010063840 Visceroptosis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 235000012677 beetroot red Nutrition 0.000 description 2
- 239000001654 beetroot red Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000002185 betanin Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- ZKOTWKIEVACBFM-QHCPKHFHSA-N ccg-35578 Chemical compound C1([C@H]2OC=3C=4C=5C=C(OC6=CC(=O)C=C(C=56)OC=4C=C(C=3CC2)OC)C=2C=CC=CC=2)=CC=CC=C1 ZKOTWKIEVACBFM-QHCPKHFHSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008738 huangbai Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- 235000008718 isoliquiritigenin Nutrition 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- MXYATHGRPJZBNA-KRFUXDQASA-N isopimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@@](C=C)(C)CC2=CC1 MXYATHGRPJZBNA-KRFUXDQASA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- MGJLSBDCWOSMHL-MIUGBVLSSA-N ononin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-MIUGBVLSSA-N 0.000 description 2
- MGJLSBDCWOSMHL-UHFFFAOYSA-N ononoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- MHVJRKBZMUDEEV-APQLOABGSA-N (+)-Pimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@](C=C)(C)C=C2CC1 MHVJRKBZMUDEEV-APQLOABGSA-N 0.000 description 1
- MSSYPWFHLFBMMP-UHFFFAOYSA-N (20S,24R)-cycloartan-3beta,6alpha,16beta,25-tetraol-3-O-beta-xylopyranoside-25-O-beta-D-glucopyranoside Natural products CC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC(C)(O2)C3C(O)CC4(C)C5CC(O)C6C(C)(C)C(CCC67CC57CCC34C)OC8OCC(O)C(O)C8O MSSYPWFHLFBMMP-UHFFFAOYSA-N 0.000 description 1
- PZRKAAPKQGONFG-UHFFFAOYSA-N (2S)-3,4-dihydro-5-methoxy-6-methyl-2-phenyl-2H-1-benzopyran-7-ol Natural products C1CC=2C(OC)=C(C)C(O)=CC=2OC1C1=CC=CC=C1 PZRKAAPKQGONFG-UHFFFAOYSA-N 0.000 description 1
- UNCVBXFEZHBZKN-AWEZNQCLSA-N (2s)-5-methoxy-2-phenyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2OC=3C=C(O)C=C(C=3CC2)OC)=CC=CC=C1 UNCVBXFEZHBZKN-AWEZNQCLSA-N 0.000 description 1
- DBKGCLWEGDYCGR-UHFFFAOYSA-N 3-(2,4-dihydroxy-6-methoxyphenyl)-1-phenylprop-2-en-1-one Chemical compound COC1=CC(O)=CC(O)=C1C=CC(=O)C1=CC=CC=C1 DBKGCLWEGDYCGR-UHFFFAOYSA-N 0.000 description 1
- FQYZLFNHAJWQNK-UHFFFAOYSA-N 3-(4,6-dihydroxy-2-methoxy-3-methylphenyl)-1-phenylprop-2-en-1-one Chemical compound COC1=C(C)C(O)=CC(O)=C1C=CC(=O)C1=CC=CC=C1 FQYZLFNHAJWQNK-UHFFFAOYSA-N 0.000 description 1
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 description 1
- PZRKAAPKQGONFG-HNNXBMFYSA-N 7-Hydroxy-5-methoxy-6-methylflavan Chemical compound C1([C@H]2OC=3C=C(O)C(C)=C(C=3CC2)OC)=CC=CC=C1 PZRKAAPKQGONFG-HNNXBMFYSA-N 0.000 description 1
- UNCVBXFEZHBZKN-UHFFFAOYSA-N 7-Hydroxy-5-methoxyflavan Natural products C1CC=2C(OC)=CC(O)=CC=2OC1C1=CC=CC=C1 UNCVBXFEZHBZKN-UHFFFAOYSA-N 0.000 description 1
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 description 1
- KWZSMZJAHIHRRT-UHFFFAOYSA-N Acetyl astragaloside I Natural products CC(=O)OC1C(OC(C)=O)C(OC(=O)C)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 KWZSMZJAHIHRRT-UHFFFAOYSA-N 0.000 description 1
- 241000746976 Agavaceae Species 0.000 description 1
- 241000334309 Amphiprion chrysopterus Species 0.000 description 1
- 241001340404 Aster tongolensis Species 0.000 description 1
- LAWPHHZXTUPSDG-UHFFFAOYSA-N Astragaloside I Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C)C1OC(=O)C LAWPHHZXTUPSDG-UHFFFAOYSA-N 0.000 description 1
- DBBFSAOZTBEFKN-UHFFFAOYSA-N Astragaloside V Natural products CC(C)(OC1OC(CO)C(O)C(O)C1O)C2COC(C)(C2)C3C(O)CC4(C)C5CC(O)C6C(C)(C)C(CCC67CC57CCC34C)OC8OCC(O)C(O)C8OC9OC(CO)C(O)C(O)C9O DBBFSAOZTBEFKN-UHFFFAOYSA-N 0.000 description 1
- KXUHEBWWYMBFBA-UHFFFAOYSA-N Astragaloside VII Natural products CC(C)(OC1OC(CO)C(O)C(O)C1O)C2COC(C)(C2)C3C(O)CC4(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C7C(C)(C)C(CCC78CC58CCC34C)OC9OCC(O)C(O)C9O KXUHEBWWYMBFBA-UHFFFAOYSA-N 0.000 description 1
- IBZLICPLPYSFNZ-UHFFFAOYSA-N Astragaloside VIII Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)OCC(O)C1O IBZLICPLPYSFNZ-UHFFFAOYSA-N 0.000 description 1
- KXHCYYSIAXMSPA-UHFFFAOYSA-N Astragaloside-I Chemical compound CC(=O)OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 KXHCYYSIAXMSPA-UHFFFAOYSA-N 0.000 description 1
- JLKGXASMCRAVAK-UHFFFAOYSA-N Astragaloside-II Natural products CC(=O)OC1C(O)C(O)COC1OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C JLKGXASMCRAVAK-UHFFFAOYSA-N 0.000 description 1
- LVBLYMQWWGLBRE-UHFFFAOYSA-N Astragaloside-II Chemical compound CC(=O)OC1C(C(COC1OC2CCC34CC35CCC6(C(C(CC6(C5CC(C4C2)OC7C(C(C(C(O7)CO)O)O)O)C)O)C8(CCC(O8)C(C)(C)O)C)C)O)O LVBLYMQWWGLBRE-UHFFFAOYSA-N 0.000 description 1
- MZILQGNQYYOFEZ-UHFFFAOYSA-N Astragaloside-V Chemical compound C1CC(C)(C2C3(CCC45CC55C(C(C(OC6C(C(O)C(O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CC5)(C)C)C(O)CC4C3(C)CC2O)C)OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O MZILQGNQYYOFEZ-UHFFFAOYSA-N 0.000 description 1
- FLPVEPQEIRRVKG-UHFFFAOYSA-N Astragaloside-VI Chemical compound O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(OC4C(C(O)C(O)CO4)OC4C(C(O)C(O)C(CO)O4)O)C4(C)C)C4C(OC4C(C(O)C(O)C(CO)O4)O)CC3C2(C)CC1O FLPVEPQEIRRVKG-UHFFFAOYSA-N 0.000 description 1
- YDELUYNKSQLCJK-UHFFFAOYSA-N Astragaloside-VII Chemical compound C1CC(C)(C2C3(CCC45CC55C(C(C(OC6C(C(O)C(O)CO6)O)CC5)(C)C)C(OC5C(C(O)C(O)C(CO)O5)O)CC4C3(C)CC2O)C)OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O YDELUYNKSQLCJK-UHFFFAOYSA-N 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 240000000163 Cycas revoluta Species 0.000 description 1
- 235000008601 Cycas revoluta Nutrition 0.000 description 1
- DJHCVWLJAINILQ-UHFFFAOYSA-N Cyclosieversioside D Natural products CC(=O)OC1C(O)C(O)COC1OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O DJHCVWLJAINILQ-UHFFFAOYSA-N 0.000 description 1
- QUUCYKKMFLJLFS-UHFFFAOYSA-N Dehydroabietan Natural products CC1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 QUUCYKKMFLJLFS-UHFFFAOYSA-N 0.000 description 1
- NFWKVWVWBFBAOV-UHFFFAOYSA-N Dehydroabietic acid Natural products OC(=O)C1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 NFWKVWVWBFBAOV-UHFFFAOYSA-N 0.000 description 1
- 240000003421 Dianthus chinensis Species 0.000 description 1
- 241001561260 Dracaena cambodiana Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- NWLKARBSFUGLOG-UHFFFAOYSA-N Isoastragaloside I Natural products CC(=O)OC1COC(OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O)C(OC(=O)C)C1O NWLKARBSFUGLOG-UHFFFAOYSA-N 0.000 description 1
- SMZYCXAYGPGYRS-NGTUZWGPSA-N Isoastragaloside II Chemical compound O[C@@H]1[C@@H](OC(=O)C)[C@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C[C@H]3[C@]4(C)C[C@H](O)[C@H]([C@]5(C)O[C@@H](CC5)C(C)(C)O)[C@@]4(C)CC[C@@]43C[C@@]42CC1 SMZYCXAYGPGYRS-NGTUZWGPSA-N 0.000 description 1
- QEQVFWRMJLHKMM-UHFFFAOYSA-N Isoastragaloside II Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O)C1O QEQVFWRMJLHKMM-UHFFFAOYSA-N 0.000 description 1
- NQRBAPDEZYMKFL-UHFFFAOYSA-N Isomucronulatol Chemical compound OC1=C(OC)C(OC)=CC=C1C1CC2=CC=C(O)C=C2OC1 NQRBAPDEZYMKFL-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000922366 Socotra Species 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- TWHPXTKPYPWOTN-UHFFFAOYSA-N Ursonic aldehyde Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C=O)CCC(C)C(C)C5C4=CCC3C21C TWHPXTKPYPWOTN-UHFFFAOYSA-N 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- SRPWHXRCOLBHSL-UHFFFAOYSA-N astragaloside III Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OCC(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C7C(C)(C)C(O)CCC78CC48CCC23C SRPWHXRCOLBHSL-UHFFFAOYSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- WHXCWJXWRVEKEB-UHFFFAOYSA-N astragaloside VI Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8OC9OC(CO)C(O)C(O)C9O WHXCWJXWRVEKEB-UHFFFAOYSA-N 0.000 description 1
- FVFSMBDVZVUETN-PTCJJXKDSA-N astragalosideiii Chemical compound O1[C@H](C(C)(O)C)CC[C@@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O FVFSMBDVZVUETN-PTCJJXKDSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- HJCCJZGOBHFQSX-UHFFFAOYSA-N cyclosieversioside B Natural products CC(CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1O)C2C(CC3(C)C4CC(O)C5C(C)(C)C(CCC56CC46CCC23C)OC7OCC(O)C(O)C7O)OC8OC(CO)C(O)C(O)C8O HJCCJZGOBHFQSX-UHFFFAOYSA-N 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- NFWKVWVWBFBAOV-MISYRCLQSA-N dehydroabietic acid Chemical compound OC(=O)[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 NFWKVWVWBFBAOV-MISYRCLQSA-N 0.000 description 1
- 229940118781 dehydroabietic acid Drugs 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- FWKBXSPDFCAHFN-DEOSSOPVSA-N dracorubin Chemical compound C1([C@H]2OC=3C=4C=5C=C(OC6=CC(=O)C(C)=C(C=56)OC=4C=C(C=3CC2)OC)C=2C=CC=CC=2)=CC=CC=C1 FWKBXSPDFCAHFN-DEOSSOPVSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SMZYCXAYGPGYRS-UHFFFAOYSA-N isoastragalosides II Natural products OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 SMZYCXAYGPGYRS-UHFFFAOYSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000001527 leucocytic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- QGPIUZIWMRUUCS-UHFFFAOYSA-N oleanolic aldehyde Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C=O)CCC(C)(C)CC5C4=CCC3C21C QGPIUZIWMRUUCS-UHFFFAOYSA-N 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- MHVJRKBZMUDEEV-KRFUXDQASA-N sandaracopimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@@](C=C)(C)C=C2CC1 MHVJRKBZMUDEEV-KRFUXDQASA-N 0.000 description 1
- YZVSLDRKXBZOMY-KNOXWWKRSA-N sandaracopimaric acid Natural products CC(=C)[C@]1(C)CCC[C@]2(C)[C@H]3CC[C@](C)(C=C)C=C3CC[C@@H]12 YZVSLDRKXBZOMY-KNOXWWKRSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 动物数(只) | OD值 |
对照组阿司匹林黄芪片血竭胶囊黄芪、血竭复方胶囊(1∶1)黄芪、血竭复方胶囊(2∶1)黄芪、血竭复方胶囊(1∶2)黄芪、血竭复方胶囊(4∶1)黄芪、血竭复方胶囊(1∶4) | -0.22.02.02.02.02.02.02.0 | 101010101010101010 | 0.190±0.080.104±0.08a0.124±0.08a0.104±0.08a0.075±0.08a,b,c0.093±0.08a0.091±0.08a0.106±0.08a0.101±0.08a |
组别 | 剂量(g/kg) | 肿胀度(mg) | 抑肿率(%) |
对照组阿司匹林黄芪片血竭胶囊黄芪、血竭复方胶囊(1∶1)黄芪、血竭复方胶囊(2∶1)黄芪、血竭复方胶囊(1∶2)黄芪、血竭复方胶囊(4∶1)黄芪、血竭复方胶囊(1∶4) | -0.22.02.02.02.02.02.02.0 | 8.9±1.83.1±1.2a4.2±1.6a3.8±1.0a2.3±1.5a,b,c2.9±1.3a2.9±1.0a3.0±0.9a3.2±1.0a | 6553577467676664 |
组别 | 致炎后肿胀率(%) | |||
1h | 2h | 4h | 6h | |
对照组阿司匹林黄芪片血竭胶囊黄芪、血竭复方胶囊(1∶1)黄芪、血竭复方胶囊(2∶1)黄芪、血竭复方胶囊(1∶2)黄芪、血竭复方胶囊(4∶1)黄芪、血竭复方胶囊(1∶4) | 71.2±11.755.1±13.7a65.2±18.260.5±15.248.2±9.8a,c53.7±15.2a57.2±14.1a59.4±16.3a58.1±15.8a | 60.±13.238.7±17.2a50.1±15.0a47.7±10.8a30.7±10.5a,b,c36.1±11.4a39.8±8.6a42.3±9.1a44.9±12.8a | 45.6±12.321.8±10.8a38.9±10.435.3±18.2a20.9±14.6a,b,c25.7±12.0a29.3±11.8a33.6±9.5a30.8±13.7a | 36.7±9.811.5±18.2a21.6±11.3a17.6±12.7a9.2±10.8a,c12.8±9.1a,b15.2±14.0a17.2±11.9a18.9±17.3a |
组别 | 菌苗注射及给药后的体温值 | ||||
1h | 2h | 3h | 4h | 5h | |
黄芪、血竭复方胶囊(1.2g/kg) | 39.3±0.6* | 39.4±0.7* | 39.1±0.7* | 39.1±0.6* | 39.1±0.5* |
黄芪、血竭复方胶囊(0.6g/kg) | 39.9±0.5* | 39.8±0.8* | 39.8±0.6* | 39.6±0.3* | 39.4±0.6* |
0.5%羧甲基纤维素钠溶液 | 40.7±0.5 | 40.98±0.6 | 41.0±0.7 | 41.0±0.5 | 40.9±0.6 |
组别 | 剂量(g/kg) | 扭体次数( X±S) | P值* |
黄芪、血竭复方胶囊黄芪、血竭复方胶囊黄芪、血竭复方胶囊阿斯匹林片对照 | 1.20.60.30.2 | 7.3±6.18.1±6.39.4±6.69.0±6.017.0±6.7 | <0.01<0.01<0.05<0.01 |
组别 | 剂量(g/kg) | 2min OD值 | 10min OD值 |
黄芪、血竭复方胶囊黄芪、血竭复方胶囊黄芪、血竭复方胶囊阿斯匹林片对照 | 1.20.60.30.2 | 0.10±0.05*0.11±0.02**0.13±0.02*0.09±0.01**0.15±0.03 | 0.08±0.02**0.11±0.02*0.11±0.02*0.10±0.01**0.13±0.02 |
组别 | 剂量(g/kg) | 两足跖厚度差(cm, X±S) | P值* |
黄芪、血竭复方胶囊黄芪、血竭复方胶囊黄芪、血竭复方胶囊阿斯匹林片对照品 | 1.20.60.30.2 | 0.03±0.010.03±0.020.05±0.020.03±0.020.08±0.03 | <0.01<0.01<0.05<0.01 |
处方1 | 处方2 | ||
黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇 | 240mg240mg20mg0.9mg适量 | 黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇 | 120mg240mg20mg0.9mg适量 |
欧巴代包衣料 | 适量 | 欧巴代包衣料 | 适量 |
处方3 | 处方4(分散片) | ||
黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇欧巴代包衣料 | 240mg120mg20mg0.9mg适量适量 | 黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇欧巴代包衣料 | 60mg240mg20mg0.9mg适量适量 |
处方1 | 处方2 | ||
黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇 | 240mg240mg20mg0.9mg适量 | 黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇 | 120mg240mg20mg0.9mg适量 |
空心胶囊 | 适量 | 空心胶囊 | 适量 |
处方3 | 处方4(分散片) | ||
黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇空心胶囊 | 240mg120mg20mg0.9mg适量适量 | 黄芪提取物血竭提取物羟丙基纤维素硬脂酸镁75%乙醇空心胶囊 | 60mg240mg20mg0.9mg适量适量 |
处方1 | 处方2 | ||
黄芪提取物血竭提取物 | 240mg240mg | 黄芪提取物血竭提取物 | 120mg240mg |
处方3 | 处方4(分散片) | ||
黄芪提取物血竭提取物 | 240mg120mg | 黄芪提取物血竭提取物 | 60mg240mg |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510001987XA CN1321666C (zh) | 2005-01-17 | 2005-01-17 | 一种包含有黄芪和血竭的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510001987XA CN1321666C (zh) | 2005-01-17 | 2005-01-17 | 一种包含有黄芪和血竭的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1660351A true CN1660351A (zh) | 2005-08-31 |
CN1321666C CN1321666C (zh) | 2007-06-20 |
Family
ID=35010088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510001987XA Expired - Fee Related CN1321666C (zh) | 2005-01-17 | 2005-01-17 | 一种包含有黄芪和血竭的药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1321666C (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1055013C (zh) * | 1997-07-02 | 2000-08-02 | 陈运祥 | 消炎退肿止痛接骨中药外敷膏的配制方法 |
CN1262943A (zh) * | 1999-02-09 | 2000-08-16 | 夏进 | 皮肤消炎、镇痛、抑疤软膏 |
-
2005
- 2005-01-17 CN CNB200510001987XA patent/CN1321666C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1321666C (zh) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1840166A (zh) | 温胆汤现代中药口服制剂及其生产方法 | |
CN104799048A (zh) | 一种增强黄沙鳖抗病能力的饲料及其制备方法 | |
CN102247479B (zh) | 一种抗肿瘤壮药及其制备方法 | |
CN104069344A (zh) | 治疗癌症的中药组合物及其制剂和制法 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
CN104288234B (zh) | 防治羊呼吸系统疾病的中药制剂及其生产方法 | |
CN103989762B (zh) | 一种清热泻腑止咳化痰的中药组合物及其制备方法 | |
CN1321666C (zh) | 一种包含有黄芪和血竭的药物组合物及其应用 | |
CN103989714A (zh) | 一种具有抗癌作用的药物组合物及其制剂 | |
CN109528984A (zh) | 一种通过涂抹乳房治疗乳腺疾病的膏霜配方及制备方法 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN108041309A (zh) | 一种可提高免疫力的仔猪有机饲料及其制备方法 | |
CN101837079B (zh) | 一种抗炎镇痛或抗炎免疫药物组合物及其制备方法和用途 | |
CN102160874B (zh) | 治疗海胆黑嘴病的复方中草药制剂 | |
CN102000303B (zh) | 一种抑制肿瘤的中药复方制剂 | |
CN106177391A (zh) | 一种治疗癌症的药物组合物及其制备方法 | |
CN109568496B (zh) | 一种治疗糖尿病的中药组合物的检测方法 | |
CN105311469A (zh) | 一种具有抗癌功效的制剂及制法 | |
CN105770445A (zh) | 一种治疗慢性萎缩性胃炎的中药制剂及其制备方法 | |
CN104800573A (zh) | 一种治疗肝癌的中药组合物及其制备方法 | |
CN104435141A (zh) | 一种含鬼箭羽的治疗糖尿病的中药组合物 | |
CN104436021A (zh) | 一种含牛蒡子的治疗糖尿病的中药组合物 | |
CN104352974A (zh) | 一种含朱砂莲的治疗糖尿病的中药组合物 | |
CN104689073A (zh) | 用于治疗阴虚毒热型肺癌的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Wang Yong Document name: Notification to Pay the Fees |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guoruitang Pharmaceutical Co., Ltd., Hainan Prov. Assignor: Yan Bin Contract record no.: 2010990000368 Denomination of invention: Combination of medication of containing astragalus root and dragon's blood resin and application Granted publication date: 20070620 License type: Exclusive License Open date: 20050831 Record date: 20100609 |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN GUORUITANG CHINESE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YAN BIN Effective date: 20101217 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570216 BRANCH 1, NO. 189, ZHONGDAN VILLAGE, HAIKOU CITY, HAINAN PROVINCE TO: 570216 WEST SIDE OF HAINAN PROVINCIAL NONGKEN HOSPITAL, BAISHUITANG ROAD, HAIKOU CITY, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101217 Address after: 570216, Hainan Province, Haikou Province on the west side of the white pond road provincial farms hospital Patentee after: HAINAN GRTANG TRADITIONAL CHINESE MEDICINE PHARMACEUTICAL CO., LTD. Address before: In the village of 570216 Hainan city of Haikou province No. 189 1 Patentee before: Yan Bin |
|
DD01 | Delivery of document by public notice |
Addressee: Wang Yong Document name: Notification of Passing Examination on Formalities |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070620 Termination date: 20140117 |